Handel Annexon, Inc. - ANNX CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.08 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.030779% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | -0.013666% | ||||||||
Gebyr natten over, tid | 22:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Tidligere luk* | 6.99 |
Åben* | 6.98 |
1-Års Ændring* | -10.28% |
Dagens Spænd* | 6.98 - 7.36 |
52-Ugers Spænd | 2.06-8.20 |
Gennemsnitlig Volumen (10 dage) | 385.50K |
Gennemsnitlig Volumen (3 måneder) | 3.50M |
Market Cap | 336.27M |
P/E-forhold | -100.00K |
Udestående aktier | 47.63M |
Omsætning | N/A |
EPS | -3.36 |
Dividend (Udbytte %) | N/A |
Beta | -100.00K |
Næste indtjeningsopgørelse | Feb 27, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 7.08 | 0.10 | 1.43% | 6.98 | 7.39 | 6.89 |
Feb 2, 2023 | 6.99 | -0.16 | -2.24% | 7.15 | 7.21 | 6.91 |
Feb 1, 2023 | 7.18 | 0.25 | 3.61% | 6.93 | 7.36 | 6.93 |
Jan 31, 2023 | 7.11 | 0.13 | 1.86% | 6.98 | 7.19 | 6.71 |
Jan 30, 2023 | 7.08 | -0.11 | -1.53% | 7.19 | 7.40 | 7.08 |
Jan 27, 2023 | 7.39 | 0.18 | 2.50% | 7.21 | 7.45 | 7.02 |
Jan 26, 2023 | 7.29 | -0.11 | -1.49% | 7.40 | 7.58 | 7.17 |
Jan 25, 2023 | 7.31 | 0.57 | 8.46% | 6.74 | 7.39 | 6.74 |
Jan 24, 2023 | 6.96 | 0.28 | 4.19% | 6.68 | 7.00 | 6.68 |
Jan 23, 2023 | 6.95 | 0.05 | 0.72% | 6.90 | 7.45 | 6.85 |
Jan 20, 2023 | 6.89 | 0.17 | 2.53% | 6.72 | 7.12 | 6.50 |
Jan 19, 2023 | 6.61 | 0.13 | 2.01% | 6.48 | 6.80 | 6.31 |
Jan 18, 2023 | 6.52 | -0.09 | -1.36% | 6.61 | 7.18 | 6.48 |
Jan 17, 2023 | 6.86 | 0.37 | 5.70% | 6.49 | 7.11 | 6.48 |
Jan 13, 2023 | 6.79 | 0.76 | 12.60% | 6.03 | 6.85 | 5.93 |
Jan 12, 2023 | 6.19 | 0.90 | 17.01% | 5.29 | 6.32 | 5.28 |
Jan 11, 2023 | 5.27 | 0.54 | 11.42% | 4.73 | 5.32 | 4.54 |
Jan 10, 2023 | 4.76 | 0.28 | 6.25% | 4.48 | 4.82 | 4.45 |
Jan 9, 2023 | 4.65 | -0.15 | -3.12% | 4.80 | 4.81 | 4.37 |
Jan 6, 2023 | 4.74 | 0.40 | 9.22% | 4.34 | 4.90 | 4.17 |
Annexon, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Total omsætning | 0 | 0 | 0 | 0 | 0 |
Totale Driftsudgifter | 20.477 | 19.112 | 32.328 | 63.469 | 130.713 |
Salgs/Generelle/Admin. Udgifter, Total | 2.624 | 3.619 | 7.994 | 14.198 | 30.647 |
Forskning & Udvikling | 17.853 | 15.528 | 24.524 | 49.271 | 100.066 |
Driftsindtægter | -20.477 | -19.112 | -32.328 | -63.469 | -130.713 |
Andre, Netto | 1.77 | 0.769 | -4.865 | 0.048 | 0.385 |
Netto Indkomst Før Skat | -18.707 | -18.303 | -37.179 | -63.412 | -130.323 |
Netto Indkomst Efter Skat | -12.923 | -18.304 | -37.183 | -63.412 | -130.323 |
Netto Indkomst Før Ekstra Ting | -12.923 | -18.304 | -37.183 | -63.412 | -130.323 |
Totale Ekstraordinære Ting | -5.785 | ||||
Netto Indkomst | -18.708 | -18.304 | -37.183 | -63.412 | -130.323 |
Total Adjustments to Net Income | -0.087 | -0.176 | -1.095 | -6.924 | 0 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -13.01 | -18.48 | -38.278 | -70.336 | -130.323 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -18.795 | -18.48 | -38.278 | -70.336 | -130.323 |
Fortyndet Netto Indkomst | -18.795 | -18.48 | -38.278 | -70.336 | -130.323 |
Fortyndet Vægtet Gennemsnit Aktier | 187.289 | 187.289 | 187.289 | 16.9624 | 38.3163 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.06946 | -0.09867 | -0.20438 | -4.14658 | -3.40124 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Fortyndet Normaliseret EPS | -0.06946 | -0.09879 | -0.20504 | -4.14658 | -3.40124 |
Usædvanlig Udgift (Indkomst) | -0.035 | -0.19 | |||
Renteindkomst (Udgift), Netto Ikke-Drift | 0.04 | 0.014 | 0.009 | 0.005 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total omsætning | 0 | 0 | 0 | 0 | 0 |
Totale Driftsudgifter | 26.202 | 31.373 | 35.68 | 37.458 | 35.426 |
Salgs/Generelle/Admin. Udgifter, Total | 5.506 | 6.801 | 8.099 | 10.241 | 8.428 |
Forskning & Udvikling | 20.696 | 24.572 | 27.581 | 27.217 | 26.998 |
Driftsindtægter | -26.202 | -31.373 | -35.68 | -37.458 | -35.426 |
Andre, Netto | 0.142 | 0.079 | 0.082 | 0.087 | 0.053 |
Netto Indkomst Før Skat | -26.06 | -31.294 | -35.598 | -37.371 | -35.373 |
Netto Indkomst Efter Skat | -26.06 | -31.294 | -35.598 | -37.371 | -35.373 |
Netto Indkomst Før Ekstra Ting | -26.06 | -31.294 | -35.598 | -37.371 | -35.373 |
Netto Indkomst | -26.06 | -31.294 | -35.598 | -37.371 | -35.373 |
Total Adjustments to Net Income | 0 | 0 | 0 | 0 | |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -26.06 | -31.294 | -35.598 | -37.371 | -35.373 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -26.06 | -31.294 | -35.598 | -37.371 | -35.373 |
Fortyndet Netto Indkomst | -26.06 | -31.294 | -35.598 | -37.371 | -35.373 |
Fortyndet Vægtet Gennemsnit Aktier | 38.2486 | 38.278 | 38.3411 | 38.481 | 38.5634 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.68133 | -0.81755 | -0.92846 | -0.97115 | -0.91727 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Fortyndet Normaliseret EPS | -0.68133 | -0.81755 | -0.92846 | -0.97115 | -0.91727 |
- Årlig
- Pr kvartal
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 4.893 | 45.706 | 45.406 | 354.011 | 247.693 |
Likvider og Kortsigtede Investeringer | 2.966 | 44.175 | 43.931 | 351.206 | 242.715 |
Likvider & Lignende | 2.966 | 44.175 | 43.931 | 268.565 | 74.843 |
Prepaid Expenses | 1.927 | 1.306 | 1.396 | 2.802 | 4.515 |
Total Assets | 7.821 | 48.149 | 49.898 | 355.946 | 287.04 |
Property/Plant/Equipment, Total - Net | 2.816 | 2.345 | 2.138 | 1.935 | 38.181 |
Property/Plant/Equipment, Total - Gross | 3.138 | 3.156 | 3.442 | 3.906 | 38.97 |
Accumulated Depreciation, Total | -0.322 | -0.811 | -1.304 | -1.971 | -0.789 |
Other Long Term Assets, Total | 0.112 | 0.098 | 2.354 | 0 | 1.166 |
Total Current Liabilities | 2.916 | 3.326 | 4.931 | 10.622 | 21.744 |
Accounts Payable | 1.524 | 1.271 | 2.371 | 3.734 | 11.153 |
Accrued Expenses | 1.074 | 1.713 | 2.194 | 6.497 | 10.452 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.318 | 0.342 | 0.366 | 0.391 | 0.139 |
Total Liabilities | 5.061 | 5.129 | 6.368 | 11.668 | 55.131 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 2.145 | 1.803 | 1.437 | 1.046 | 33.387 |
Total Equity | 2.76 | 43.02 | 43.53 | 344.278 | 231.909 |
Redeemable Preferred Stock | 48.971 | 107.222 | 143.984 | 0 | 0 |
Common Stock | 0.003 | 0.004 | 0.004 | 0.038 | 0.039 |
Additional Paid-In Capital | 0.905 | 1.257 | 2.202 | 510.309 | 528.365 |
Retained Earnings (Accumulated Deficit) | -47.093 | -65.397 | -102.58 | -165.992 | -296.315 |
Other Equity, Total | -0.026 | -0.066 | -0.08 | -0.077 | -0.18 |
Total Liabilities & Shareholders’ Equity | 7.821 | 48.149 | 49.898 | 355.946 | 287.04 |
Total Common Shares Outstanding | 187.289 | 187.289 | 187.289 | 38.1576 | 38.5608 |
Totale Tilgodehavender, Netto | 0.225 | 0.079 | 0.003 | 0 | |
Kortsigtede Investeringer | 82.641 | 167.872 | |||
Other Current Assets, Total | 0.463 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 330.522 | 304.393 | 275.498 | 247.693 | 211.254 |
Likvider og Kortsigtede Investeringer | 326.654 | 302.386 | 271.367 | 242.715 | 206.659 |
Likvider & Lignende | 206.669 | 99.588 | 68.519 | 74.843 | 112.828 |
Kortsigtede Investeringer | 119.985 | 202.798 | 202.848 | 167.872 | 93.831 |
Totale Tilgodehavender, Netto | 0.038 | 0 | 0.231 | 0 | |
Prepaid Expenses | 3.83 | 2.007 | 3.9 | 4.515 | 4.461 |
Total Assets | 333.117 | 331.784 | 310.156 | 287.04 | 250.569 |
Property/Plant/Equipment, Total - Net | 1.429 | 26.225 | 32.899 | 38.181 | 37.908 |
Accumulated Depreciation, Total | -2.509 | -3.047 | -3.607 | -0.789 | -1.295 |
Other Long Term Assets, Total | 1.166 | 1.166 | 1.759 | 1.166 | 1.407 |
Total Current Liabilities | 10.695 | 10.284 | 11.919 | 21.744 | 17.053 |
Accounts Payable | 4.518 | 4.184 | 4.797 | 11.153 | 9.378 |
Accrued Expenses | 5.779 | 6.1 | 7.122 | 10.452 | 7.486 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.398 | 0 | 0 | 0.139 | 0.189 |
Total Liabilities | 11.641 | 36.449 | 45.679 | 55.131 | 49.955 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.946 | 26.165 | 33.76 | 33.387 | 32.902 |
Total Equity | 321.476 | 295.335 | 264.477 | 231.909 | 200.614 |
Common Stock | 0.038 | 0.038 | 0.038 | 0.039 | 0.039 |
Additional Paid-In Capital | 513.539 | 518.708 | 523.458 | 528.365 | 532.636 |
Retained Earnings (Accumulated Deficit) | -191.998 | -223.346 | -258.944 | -296.315 | -331.688 |
Other Equity, Total | -0.103 | -0.065 | -0.075 | -0.18 | -0.373 |
Total Liabilities & Shareholders’ Equity | 333.117 | 331.784 | 310.156 | 287.04 | 250.569 |
Total Common Shares Outstanding | 38.2587 | 38.3323 | 38.3749 | 38.5608 | 38.5636 |
Property/Plant/Equipment, Total - Gross | 25.112 | 38.97 | 39.203 | ||
Other Current Assets, Total | 0.463 | 0.134 | |||
Redeemable Preferred Stock | 0 |
- Årlig
- Pr kvartal
2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|
Netto indkomst/Startlinje | -18.708 | -18.304 | -37.183 | -63.412 | -130.323 |
Likvider Fra Driftsaktiviteter | -19.26 | -17.19 | -28.358 | -53.087 | -106.11 |
Likvider Fra Driftsaktiviteter | 0.271 | 0.488 | 0.493 | 0.667 | 2.141 |
Ikke-Likvide Ting | 0.401 | 0.148 | 7.707 | 4.941 | 18.927 |
Cash Taxes Paid | 0.001 | 0.001 | 0.002 | 0 | |
Ændringer i Driftskapital | -1.224 | 0.478 | 0.625 | 4.717 | 3.145 |
Likvider fra Investeringsaktiviteter | -0.567 | -0.017 | -0.267 | -83.164 | -88.236 |
Kapitaludgifter | -0.567 | -0.017 | -0.267 | -0.464 | -1.654 |
Likvider fra Financieringsaktiviteter | 0.042 | 58.456 | 28.395 | 360.876 | 1.795 |
Udstedelse (Pensionering) af Aktier, Netto | 0.042 | 58.456 | 30 | 363.85 | 1.795 |
Udenlandsk Børs Effekter | -0.024 | -0.04 | -0.014 | 0.009 | -0.005 |
Netto Ændring i Likviditet | -19.809 | 41.209 | -0.244 | 224.634 | -192.556 |
Financiering af Cash-Flow-Ting | 0 | -1.605 | -2.974 | 0 | |
Andre Investerings-Cash-Flow-Ting, Total | -82.7 | -86.582 | |||
Udstedelse (Pensionering) af Gæld, Netto | 0 | 0 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -26.006 | -57.354 | -92.952 | -130.323 | -35.373 |
Cash From Operating Activities | -23.416 | -48.074 | -77.789 | -106.11 | -30.288 |
Cash From Operating Activities | 0.538 | 1.076 | 1.635 | 2.141 | 0.518 |
Non-Cash Items | 3.142 | 8.469 | 13.767 | 18.927 | 4.671 |
Changes in Working Capital | -1.09 | -0.265 | -0.239 | 3.145 | -0.104 |
Cash From Investing Activities | -37.581 | -120.655 | -121.933 | -88.236 | 68.251 |
Capital Expenditures | -0.032 | -0.032 | -0.799 | -1.654 | -5.214 |
Other Investing Cash Flow Items, Total | -37.549 | -120.623 | -121.134 | -86.582 | 73.465 |
Cash From Financing Activities | 0.268 | 0.92 | 0.847 | 1.795 | 0.019 |
Financing Cash Flow Items | 0 | 0 | -0.395 | 0 | |
Issuance (Retirement) of Stock, Net | 0.268 | 0.92 | 1.242 | 1.795 | 0.019 |
Foreign Exchange Effects | -0.001 | -0.002 | -0.005 | -0.005 | 0.003 |
Net Change in Cash | -60.73 | -167.811 | -198.88 | -192.556 | 37.985 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
Satter Management Co., L.P. | Private Equity | 9.2566 | 4408966 | 0 | 2022-09-30 | LOW |
BVF Partners L.P. | Hedge Fund | 7.9376 | 3780694 | 0 | 2022-09-30 | LOW |
Eventide Asset Management, LLC | Investment Advisor | 7.6139 | 3626508 | 0 | 2022-09-30 | LOW |
Bain Capital Life Sciences Investors, LLC | Investment Advisor | 7.5622 | 3601926 | 360298 | 2022-09-30 | LOW |
Adage Capital Management, L.P. | Hedge Fund | 7.5435 | 3592975 | 54200 | 2022-09-30 | LOW |
Redmile Group, LLC | Investment Advisor/Hedge Fund | 7.3549 | 3503190 | 0 | 2022-09-30 | LOW |
Fairmount Funds Management LLC | Hedge Fund | 7.0513 | 3358563 | 465963 | 2022-09-30 | MED |
VR Adviser, LLC | Venture Capital | 6.7605 | 3220050 | 1291573 | 2022-09-30 | LOW |
Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 6.4199 | 3057800 | 0 | 2022-12-31 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 4.7422 | 2258711 | 29656 | 2022-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.2342 | 1540467 | 241273 | 2022-09-30 | LOW |
Citadel Advisors LLC | Hedge Fund | 2.9521 | 1406105 | -77558 | 2022-09-30 | HIGH |
Driehaus Capital Management, LLC | Investment Advisor/Hedge Fund | 2.7117 | 1291572 | 1291572 | 2022-09-30 | MED |
Woodline Partners LP | Hedge Fund | 2.6491 | 1261770 | 852140 | 2022-09-30 | HIGH |
Novartis AG | Corporation | 1.9121 | 910747 | -1196497 | 2021-12-31 | LOW |
Clarus Ventures, LLC | Venture Capital | 1.911 | 910211 | 0 | 2022-09-30 | MED |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.83 | 871647 | 171329 | 2022-09-30 | LOW |
MFS Investment Management | Investment Advisor/Hedge Fund | 1.6421 | 782132 | 52390 | 2022-09-30 | LOW |
Deerfield Management Company, L.P. | Hedge Fund | 1.2259 | 583913 | 0 | 2022-09-30 | MED |
Millennium Management LLC | Hedge Fund | 1.1514 | 548412 | 140413 | 2022-09-30 | HIGH |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com GroupHandlende
Månedlkige, aktive klienter
Månedlig investeringsvolumen
Hævet hver måned
Handelslommeregner
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Annexon, Inc. Company profile
Om Annexon, Inc.
Annexon, Inc. er en biofarmaceutisk virksomhed i den kliniske fase, der udvikler en række behandlinger til patienter med klassiske komplementmedierede sygdomme i kroppen, hjernen og øjet. Selskabets produktkandidat, ANX005, er et fuldlængde monoklonalt antistof, der er formuleret til intravenøs administration ved autoimmune og neurodegenerative sygdomme. Produktkandidaten ANX007 er et antigenbindende fragment (Fab), der er formuleret til intravitreal administration til behandling af neurodegenerative øjensygdomme. Virksomheden er også ved at udvikle ANX009, som er en subkutan formulering af et Fab til behandling af systemiske autoimmune sygdomme. Virksomheden har afsluttet kliniske fase 1b sikkerheds- og doseringsforsøg for ANX005 og ANX007 i patienter med henholdsvis Guillain-Barre syndrom (GBS) og glaukom. Der gennemføres også kliniske forsøg med flere alvorlige autoimmune, neurodegenerative og oftalmiske sygdomme.
Industry: | Biopharmaceuticals |
1400 Sierra Point Parkway
Bldg C Suite 200
BRISBANE
CALIFORNIA 94005
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 485.000+ handlende over hele verden, der valgte at handle hos Capital.com